SG11201807783UA - Mutant bordetella strains and methods for use - Google Patents
Mutant bordetella strains and methods for useInfo
- Publication number
- SG11201807783UA SG11201807783UA SG11201807783UA SG11201807783UA SG11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA
- Authority
- SG
- Singapore
- Prior art keywords
- lille
- international
- subject
- institut
- calmette
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314843P | 2016-03-29 | 2016-03-29 | |
| PCT/EP2017/057468 WO2017167834A1 (en) | 2016-03-29 | 2017-03-29 | Mutant bordetella strains and methods for use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807783UA true SG11201807783UA (en) | 2018-10-30 |
Family
ID=58488973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807783UA SG11201807783UA (en) | 2016-03-29 | 2017-03-29 | Mutant bordetella strains and methods for use |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10682377B2 (https=) |
| EP (2) | EP4541809A3 (https=) |
| JP (1) | JP6993984B2 (https=) |
| CN (2) | CN109069535B (https=) |
| AU (2) | AU2017242541B2 (https=) |
| DK (1) | DK3436034T3 (https=) |
| ES (1) | ES3027194T3 (https=) |
| FI (1) | FI3436034T3 (https=) |
| SG (1) | SG11201807783UA (https=) |
| WO (1) | WO2017167834A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800244A1 (en) * | 2006-03-10 | 2021-04-07 | Institut Pasteur de Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| CA2759280C (en) | 2009-04-28 | 2016-09-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| CN109069535B (zh) * | 2016-03-29 | 2022-03-18 | 里尔巴斯德研究所 | 突变型博德特氏菌属菌株及其使用方法 |
| CA3077428A1 (en) | 2017-10-18 | 2019-04-25 | Institut Pasteur De Lille | Bordetella strains expressing serotype 3 fimbriae |
| CN116322756A (zh) | 2020-08-14 | 2023-06-23 | 伊利亚特生物技术有限责任公司 | 经冻干的活鲍特菌属疫苗 |
| EP4247397A4 (en) | 2020-11-17 | 2024-11-06 | Iliad Biotechnologies, LLC | TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES |
| EP4558169A1 (en) | 2022-07-22 | 2025-05-28 | Institut National de la Santé et de la Recherche Médicale | Use of bordetella strains for the treatment of chronic obstructive pulmonary disease |
| WO2025257397A1 (en) | 2024-06-14 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713072B1 (en) | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
| GB9115332D0 (en) * | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
| FR2718750B1 (fr) | 1994-04-19 | 1996-06-14 | Pasteur Institut | Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants. |
| US6051240A (en) * | 1994-04-28 | 2000-04-18 | Takeda Chemical Industries, Ltd. | Method of separating protective components of Bordetella pertussis |
| FR2754543B1 (fr) * | 1996-10-11 | 1998-12-31 | Pasteur Institut | Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires |
| FR2840319B1 (fr) | 2002-05-30 | 2004-08-20 | Pasteur Institut | Souches de bordetella rendues deficientes par attenuation genetique |
| CA2522007A1 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Methods of preventing or treating respiratory conditions |
| EP3800244A1 (en) | 2006-03-10 | 2021-04-07 | Institut Pasteur de Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| DK2069503T3 (da) | 2006-11-15 | 2016-02-15 | Folia Biotech Inc | Papayamosaikvirus-baserede vacciner mod influenza |
| EP2134359A4 (en) | 2007-02-23 | 2010-06-16 | Penn State Res Found | USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR |
| CA2690641A1 (en) | 2007-06-18 | 2008-12-24 | Hemispherx Biopharma, Inc. | Early intervention of viral infections with immune activators |
| CA2759280C (en) * | 2009-04-28 | 2016-09-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| WO2010146414A1 (en) | 2009-06-15 | 2010-12-23 | National University Of Singapore | Influenza vaccine, composition, and methods of use |
| CN104302314B (zh) * | 2011-11-02 | 2020-06-02 | 新加坡国立大学 | 减毒博代氏杆菌菌株对抗变应性疾病的效果 |
| CN102793915B (zh) * | 2012-07-25 | 2013-10-23 | 天津康希诺生物技术有限公司 | 一种无细胞百日咳疫苗的生产方法 |
| EP2722338A1 (en) | 2012-10-17 | 2014-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel recombinant Bordetella strains |
| CN109069535B (zh) * | 2016-03-29 | 2022-03-18 | 里尔巴斯德研究所 | 突变型博德特氏菌属菌株及其使用方法 |
-
2017
- 2017-03-29 CN CN201780021384.7A patent/CN109069535B/zh active Active
- 2017-03-29 SG SG11201807783UA patent/SG11201807783UA/en unknown
- 2017-03-29 JP JP2018551960A patent/JP6993984B2/ja active Active
- 2017-03-29 ES ES17715426T patent/ES3027194T3/es active Active
- 2017-03-29 AU AU2017242541A patent/AU2017242541B2/en active Active
- 2017-03-29 WO PCT/EP2017/057468 patent/WO2017167834A1/en not_active Ceased
- 2017-03-29 EP EP25158892.7A patent/EP4541809A3/en active Pending
- 2017-03-29 DK DK17715426.7T patent/DK3436034T3/da active
- 2017-03-29 US US15/472,436 patent/US10682377B2/en active Active
- 2017-03-29 CN CN202210315642.5A patent/CN114767718A/zh active Pending
- 2017-03-29 FI FIEP17715426.7T patent/FI3436034T3/fi active
- 2017-03-29 EP EP17715426.7A patent/EP3436034B1/en active Active
-
2020
- 2020-04-30 US US16/863,972 patent/US11065276B2/en active Active
-
2021
- 2021-06-02 US US17/337,367 patent/US20210290667A1/en not_active Abandoned
-
2022
- 2022-08-24 AU AU2022221438A patent/AU2022221438B2/en active Active
-
2023
- 2023-06-20 US US18/338,314 patent/US20230381224A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3027194T3 (en) | 2025-06-13 |
| CA3018126A1 (en) | 2017-10-05 |
| FI3436034T3 (fi) | 2025-05-08 |
| AU2017242541A1 (en) | 2018-10-11 |
| EP3436034B1 (en) | 2025-03-26 |
| WO2017167834A1 (en) | 2017-10-05 |
| CN114767718A (zh) | 2022-07-22 |
| AU2017242541B2 (en) | 2022-06-30 |
| US20170283890A1 (en) | 2017-10-05 |
| EP3436034A1 (en) | 2019-02-06 |
| US20230381224A1 (en) | 2023-11-30 |
| US10682377B2 (en) | 2020-06-16 |
| CN109069535A (zh) | 2018-12-21 |
| JP6993984B2 (ja) | 2022-02-03 |
| US20210290667A1 (en) | 2021-09-23 |
| JP2019513722A (ja) | 2019-05-30 |
| AU2022221438B2 (en) | 2024-10-03 |
| DK3436034T3 (da) | 2025-05-12 |
| AU2022221438A1 (en) | 2022-10-06 |
| US20200323901A1 (en) | 2020-10-15 |
| US11065276B2 (en) | 2021-07-20 |
| EP4541809A3 (en) | 2025-06-25 |
| CN109069535B (zh) | 2022-03-18 |
| EP4541809A2 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807783UA (en) | Mutant bordetella strains and methods for use | |
| SG11201807195VA (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201805835WA (en) | Modified oncolytic virus | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201901351UA (en) | A patient interface, system and method | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors |